Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes
- PMID: 9700508
- DOI: 10.1111/j.1600-065x.1998.tb01194.x
Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes
Abstract
Class I proteins are responsible for binding proteins from endogenously synthesized proteins and displaying them on the cell surface. Our understanding of this process has reached the point where we can manipulate the biochemical properties of peptide/class I binding and determine the effects of this alteration on subsequent immune responses. In this article, we will review the biochemistry of peptide/class I binding, and the effects of structure on this interaction between class I proteins and their peptide ligands. We will review the data which suggest that the major relevant biochemical parameter of class I peptide binding is the off-rate. We will show that the design of altered ligands with improved binding, thermostability and immunogenicity is possible.
Similar articles
-
Breaking tolerance with engineered class I antigen-presenting molecules.Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3136-3145. doi: 10.1073/pnas.1807465116. Epub 2019 Feb 6. Proc Natl Acad Sci U S A. 2019. PMID: 30728302 Free PMC article.
-
Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules.Int Immunol. 1993 Sep;5(9):1129-38. doi: 10.1093/intimm/5.9.1129. Int Immunol. 1993. PMID: 8241055
-
Do T cells need endogenous peptides for activation?Nat Rev Immunol. 2008 Nov;8(11):895-900. doi: 10.1038/nri2431. Nat Rev Immunol. 2008. PMID: 18846098 Review.
-
Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation.Int Immunol. 2005 Dec;17(12):1607-17. doi: 10.1093/intimm/dxh340. Epub 2005 Nov 1. Int Immunol. 2005. PMID: 16263755
-
On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).Int Arch Allergy Immunol. 2016;170(4):211-233. doi: 10.1159/000448756. Epub 2016 Sep 20. Int Arch Allergy Immunol. 2016. PMID: 27642756 Free PMC article. Review.
Cited by
-
A novel combination approach to effectively reduce inflammation and neurodegeneration in multiple sclerosis models.Neurochem Int. 2024 May;175:105697. doi: 10.1016/j.neuint.2024.105697. Epub 2024 Feb 15. Neurochem Int. 2024. PMID: 38364938 Free PMC article.
-
Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu.Mol Immunol. 2007 Jan;44(4):322-31. doi: 10.1016/j.molimm.2006.02.027. Epub 2006 Apr 4. Mol Immunol. 2007. PMID: 16597462 Free PMC article.
-
Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.J Clin Invest. 1999 Nov;104(10):1449-57. doi: 10.1172/JCI7936. J Clin Invest. 1999. PMID: 10562307 Free PMC article.
-
Rational design of peptide-based tumor vaccines.Pharm Res. 2002 Jul;19(7):926-32. doi: 10.1023/a:1016497818471. Pharm Res. 2002. PMID: 12180543 Review.
-
Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.Cell Rep. 2019 Apr 30;27(5):1434-1445.e3. doi: 10.1016/j.celrep.2019.04.016. Cell Rep. 2019. PMID: 31042471 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials